| Bioactivity | Bempegaldesleukin (NKTR-214), a PEGylated interleukin-2 (IL-2), is an immunostimulatory IL-2 prodrug acting as a CD122-preferential IL-2 pathway agonist. Bempegaldesleukin can stimulate an antitumor immune response[1]. |
| Invitro | Bempegaldesleukin 是一种 IL-2 前体药物，经过改造可提供受控、持续和优先的 IL-2 通路信号，目的是刺激抗肿瘤免疫反应，同时最大限度地降低毒性[1]。 |
| In Vivo | Bempegaldesleukin (0.8 mg/kg; i.v. for 7 d) + NKTR-262 以 CD8+ T 细胞依赖性方式显着改善两种肿瘤模型 (CT26 和 EMT6) 的存活率[2]。 |
| Name | Bempegaldesleukin |
| CAS | 1939126-74-5 |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
| Reference | [1]. Tannir NM, et, al. Bempegaldesleukin plus nivolumab in first-line renal cell carcinoma: results from the PIVOT-02 study. J Immunother Cancer. 2022 Apr;10(4):e004419. [2]. Rolig AS, et, al. Combining bempegaldesleukin (CD122-preferential IL-2 pathway agonist) and NKTR-262 (TLR7/8 agonist) improves systemic antitumor CD8+ T cell cytotoxicity over BEMPEG+RT. J Immunother Cancer. 2022 Apr;10(4):e004218. |